On November 5, reports emerged that Isomorphic Labs, Alphabet's AI-driven drug discovery company, is in discussions for a new funding round to raise approximately $5 billion, with a valuation that could reach $50 billion. The company was spun out of Google DeepMind in 2021 and focuses on leveraging artificial intelligence to accelerate drug discovery. In May of this year, it completed a $2.1 billion funding round led by Thrive Capital, with participation from Alphabet and other investors.